AX-2026-041705 · Hexarelin · QSC lot QSC-2601-N9656

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	99.60	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.40	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — oxidised Trp (+16 Da)	0.21	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	87.28	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	86.93	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	12.36	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	10.745	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	107.5	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	6.12	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	6.28	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.32	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	7.28	EU/mg	≤ 5.0	FAIL
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	White powder, no defined cake (melt-back)	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.76	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	8.44	min	8.37 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.01	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	86,812	—	≥ 20,000	PASS
Resolution to nearest impurity	vs C-terminal free acid (+1 Da)	1.27	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 86,812, and skew follows the reported asymmetry factor of 1.01. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.21 % impurity against a 99.60 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Hexarelin — main peak	8.44	4,840,869	99.60	—
2	oxidised Trp (+16 Da)	8.12	10,207	0.21	+15.995
3	des-methyl hexarelin (GHRP-6, −14 Da)	7.99	6,318	0.13	-14.016
4	C-terminal free acid (+1 Da)	8.59	1,458	0.03	+0.984
5	des-Lys (−128 Da)	8.23	1,458	0.03	-128.095
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	6.12
Counter-ion (acetate)	ion chromatography	6.28
Residual solvent + inorganic residue	estimated	0.32
Total peptide content	by difference	87.28
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.60	divergence +0.16 pp vs batch median
Total impurities (% area)	0.10	0.40
Largest single impurity (% area)	not stated	0.21
Water (%)	not stated	6.12
Counter-ion (%)	6.2	6.28
Peptide content (%w/w)	89.7	87.28
Endotoxin (EU/mg)	not stated	7.28
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 5 d) → assay. Submitter did not handle the vial.
Assay date: 21 Apr 2026
Submitted to the index: 17 May 2026
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

lal_assay17 May 2026

7.28 EU/mg is above the index screening threshold of 5.0. Two things to keep separate: the index threshold is a screening figure, and a real limit is dose-dependent. The endotoxin dose-limit calculator does that arithmetic. What this record establishes is that the burden is measurable and high relative to the rest of the dataset.

lot_traceability17 May 2026

No endotoxin figure on this record, which is true of roughly three quarters of the index. It is the one measurement that cannot be inferred from any other and the one most often omitted.

ftir_amide_i17 May 2026

High endotoxin 7.28 EU/mg on high-purity material vs purity suggests water quality at the fill step. If the lot was lyophilised from non-purified water, this is the expected finding.

underfill_3to117 May 2026

7.28 EU/mg from an older lot. Endotoxins are heat-stable and drift is rare. If this matches fresh-lot median from the same supplier, the number is stable.

Section 7

Related records

Same batch — lot QSC-2601-N9656 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041703	QSC-2601-N9656	Medutest	2026-Q2	99.77	5.65	103.3	Supplier-supplied	0	PASS
AX-2026-041704	QSC-2601-N9656	Medutest	2026-Q2	99.74	6.27	—	Supplier-supplied	1	MARGINAL
AX-2026-041706	QSC-2601-N9656	PeptideMeter	2026-Q2	99.57	5.88	—	Supplier-supplied	1	MARGINAL
AX-2026-041707	QSC-2601-N9656	Janoshik	2026-Q2	99.74	5.68	104.8	Supplier-supplied	1	FAIL
AX-2026-041708	QSC-2601-N9656	VendorInvestigate	2026-Q2	99.57	5.92	90.4	Buyer-sourced	2	FAIL
AX-2026-041709	QSC-2601-N9656	Janoshik	2026-Q2	99.84	5.39	—	Supplier-supplied	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Hexarelin records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041892	JEEP	JEEP-2608-Y4367	Janoshik	2026-Q3	99.55	3.61	98.9	Supplier-supplied	1	MARGINAL
AX-2026-041893	JEEP	JEEP-2608-Y4367	PeptideMeter	2026-Q3	99.44	3.58	103.2	Supplier-supplied	0	PASS
AX-2026-043049	KP	KP-2604-X5435	Nordanalyt	2026-Q2	98.46	3.64	103.0	Buyer-sourced	2	FAIL
AX-2026-043279	CPC	CPC-2511-F1491	PeptideMeter	2026-Q2	98.87	5.35	—	Supplier-supplied	2	FAIL
AX-2026-042137	Homopeptide	HOMO-2602-R8195	Janoshik	2026-Q2	99.93	3.94	90.6	Supplier-supplied	1	MARGINAL
AX-2026-043048	KP	KP-2604-X5435	VendorInvestigate	2026-Q2	98.28	3.15	94.2	Buyer-sourced	2	FAIL
AX-2026-043274	CPC	CPC-2511-F1491	PeptideMeter	2026-Q2	98.89	5.10	—	Supplier-supplied	2	FAIL
AX-2026-043046	KP	KP-2604-X5435	Nordanalyt	2026-Q2	99.00	3.50	—	Supplier-supplied	2	MARGINAL

Other recent QSC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041683	CJC-1295 (no DAC)	QSC-2606-V8637	Janoshik	2026-Q3	99.93	3.63	97.1	Supplier-supplied	1	FAIL
AX-2026-041727	CJC-1295 with DAC	QSC-2602-E9474	Janoshik	2026-Q3	98.88	6.62	105.3	Supplier-supplied	1	MARGINAL
AX-2026-041728	CJC-1295 with DAC	QSC-2602-E9474	VendorInvestigate	2026-Q3	98.42	7.04	—	Buyer-sourced	1	MARGINAL
AX-2026-041734	CJC-1295 with DAC	QSC-2602-E9474	Medutest	2026-Q3	99.43	7.17	105.5	Supplier-supplied	2	FAIL
AX-2026-041652	Liraglutide	QSC-2605-W8602	Nordanalyt	2026-Q3	99.33	6.55	—	Supplier-supplied	0	PASS
AX-2026-041730	CJC-1295 with DAC	QSC-2602-E9474	PeptideMeter	2026-Q3	98.79	6.93	95.4	Supplier-supplied	1	MARGINAL
AX-2026-041686	CJC-1295 (no DAC)	QSC-2606-V8637	Janoshik	2026-Q3	99.93	4.04	—	Supplier-supplied	0	PASS
AX-2026-041653	Liraglutide	QSC-2605-W8602	VendorInvestigate	2026-Q3	98.82	5.95	—	Buyer-sourced	0	PASS